Liver Disease

December 20th 2023

There is no vaccine against the hepatitis C virus. A subscription-like payment model may help overcome some of the cost issues posed by direct-acting antivirals.

December 7th 2023

If approved, elafibranor would be a second-line treatment for patients with primary biliary cholangitis. The Prescription Drug User Fee Act action date is June 10, 2024.

December 5th 2023

The authors found that patients who received DAA treatment had a five-year survival rate of 47.2% compared with 35.2% for untreated patients.

December 5th 2023

Researchers from the Centers for Disease Control and Prevention identified 315 deaths from hepatitis A.